What's in that crock at the end of the rainbow? The link between science and stock hype
The first lesson in IR 101 is 'no surprises.' Would investors be surprised to find out that the eminently respectable scientists whose published research they are reading have stock options whose value hinges on those results?
It is mostly in the biotech and pharmaceutical fields that scientific papers have financial implications. Many companies either circulate reprints to investors, or at least point them out to analysts. The scientists from long-established companies like Genentech or
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495
